Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Tom Froggatt. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tom Froggatt or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Dave Hallett, Recursion

44:16
 
Share
 

Manage episode 471194202 series 3141589
Content provided by Tom Froggatt. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tom Froggatt or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

This week on Careers in Discovery, we welcome back Dave Hallett, now Chief Scientific Officer at Recursion, following the recent merger with Exscientia.

The last five years have been transformative for Dave, from leading AI-driven drug discovery at Exscientia to navigating one of Biotech’s biggest IPOs and stepping into the CEO role in a challenging market. Now, he’s focused on proving that AI-designed medicines can deliver real impact, with clinical results beginning to emerge.

We discuss the evolution of AI in drug discovery, the lessons Dave has learned leading a publicly listed company, and why the industry must focus on reducing drug development failure rates to make new medicines more accessible.

A fascinating conversation with a leader at the forefront of Biotech innovation.

  continue reading

102 episodes

Artwork
iconShare
 
Manage episode 471194202 series 3141589
Content provided by Tom Froggatt. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tom Froggatt or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

This week on Careers in Discovery, we welcome back Dave Hallett, now Chief Scientific Officer at Recursion, following the recent merger with Exscientia.

The last five years have been transformative for Dave, from leading AI-driven drug discovery at Exscientia to navigating one of Biotech’s biggest IPOs and stepping into the CEO role in a challenging market. Now, he’s focused on proving that AI-designed medicines can deliver real impact, with clinical results beginning to emerge.

We discuss the evolution of AI in drug discovery, the lessons Dave has learned leading a publicly listed company, and why the industry must focus on reducing drug development failure rates to make new medicines more accessible.

A fascinating conversation with a leader at the forefront of Biotech innovation.

  continue reading

102 episodes

Alla avsnitt

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play